Verve Therapeutics, Inc.
NASDAQ: VERV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sekar Kathiresan
- Employees
- 274
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $994.0M
- Website
- https://www.vervetx.com
Loading VERV…
Loading profile data…Frequently asked questions about VERV
What does Verve Therapeutics, Inc. (VERV) do?
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progres...
Where does VERV trade?
Verve Therapeutics, Inc. (VERV) trades on the NASDAQ Global Select.
What sector is VERV in?
Verve Therapeutics, Inc. (VERV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Verve Therapeutics, Inc.?
Sekar Kathiresan is the chief executive officer of Verve Therapeutics, Inc. (VERV).
Where is Verve Therapeutics, Inc. headquartered?
Verve Therapeutics, Inc. is headquartered in United States.
Does VERV pay a dividend?
Verve Therapeutics, Inc. (VERV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VERV go public?
Verve Therapeutics, Inc. (VERV) completed its initial public offering in 2021.